

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



Nadine Piorkowsky, ELPA
for
ANGELOS HATZAKIS

PROFESSOR OF EPIDEMIOLOGY & PREVENTIVE MEDICINE
DIRECTOR, DPT OF HYGIENE, EPIDEMIOLOGY & MEDICAL STATISTICS
ATHENS UNIVERSITY MEDICAL SCHOOL

Budapest 18-19. March 2010, VHPB Meeting

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



- ← Viral hepatitis constitutes one of the most widespread and rapidly growing public health problems faced by developed and developing countries.
- ← Implications of Hepatitis B and C are still poorly understood at a political and a public level

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



- A. Conference on Hepatitis B and C focusing on engaging policy makers, stakeholders and key opinion leaders in EU who can affect policy change.
- B. Fast track research and pooled analyses of existing data to support a comprehensive public health strategy for HBV/HCV in Europe.

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



CORE STEERING GROUP(1)

Co-Chairs

- Angelos Hatzakis – Athens University Medical School
- Nadine Piorkowsky – European Liver Patients Association (ELPA)
- Massimo Colombo – University of Milan

Treasurer

- Rafael Esteban – Vall d' Hebron University Hospital, Barcelona

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



CORE STEERING GROUP (2)

Members

- Manuel Carballo – International Centre for Migration & Health
- Charles Gore – World Hepatitis Alliance/ The Hepatitis C Trust
- Harry Janssen - Erasmus University
- Michael Manns - Hannover Medical School
- Patrick Marcellin - University of Paris
- George Papatheodoridis – Athens University
- Howard Thomas - Imperial College, London
- Heiner Wedemeyer – Hannover Medical School (EASL)
- Dominique Valla - University of Paris VII, France (EASL)

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



ADVISORY BOARD

- ❖ European Centre for Disease Control & Prevention (ECDC) - *(M. van de Laar)*
- ❖ Viral Hepatitis Prevention Board (VHPB) – *(P. van Damme)*
- ❖ WHO (invited)

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



ENDORSEMENT

- ❖ European Commission
- ❖ Belgian Government
- ❖ World Health Organisation (WHO)
- ❖ European Centre for Disease Control (ECDC)
- ❖ Viral Hepatitis Prevention Board (VHPB)
- ❖ European Association for the Study of the Liver (EASL)
- ❖ European Liver Patients Association (ELPA)

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



RESEARCH PRIORITIES

- ❖ Prevalence of HBV and HCV in Europe (EU 27) - ECDC
- ❖ Burden of HBV and HCV disease in Europe (EU 27) - ECDC
- ❖ Cost effectiveness of HBV and HCV screening
- ❖ Migration and HBV/HCV in Europe: Barriers to prevention and treatment
- ❖ Patient self-help in the EU Member States

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



DELIVERABLES

1. Awareness and Prevention
2. Enhancing Surveillance for HBV and HCV by ECDC
3. Screening/case findings for HBV/HCV and Related Diseases where co-infection is common
4. Universal Access to Early Treatment in line with Evidence-Based Guidelines
5. Expansion of research resources under the 7th and 8th Research Framework Programmes of the EU

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



Awareness and Prevention (1)

- Public Awareness campaigns
- HBV vaccine
- Social integration of individuals infected with HBV and HCV
- Reassessment of HBV vaccination policies
- Immigrants
- Protection of IVDU and prisoners
- Health care workers and other occupationally exposed
- Blood donors

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



Awareness and Prevention (2)

- Pregnant women and newborns
- HIV infected persons
- Household contacts
- Persons with STD
- International travellers
- Hemodialysis patients
- Integration of prevention into existing public health frameworks

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



Enhancing Surveillance for HBV and HCV by ECDC

- Acceleration and maintenance of European-wide surveillances
- Mandatory notification of Chronic Disease.

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



Screening/Detection for HBV/HCV and Related Diseases where co-infection is common

- Indicator disease / risk factor screening
- Cost-effectiveness of screening
- Legal and ethical implication of screening
- Guidance on settings where HBV screening is offered
- Antenatal screening
- Availability of risk group screening, such as migrants or IDUs
- Blood donor screening
- Screening for Hepatocellular carcinoma
- Engagement of local community leaders to encourage screening

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



Universal Access to Early Treatment in line with Evidence-Based Guidelines

- Earlier use of effective treatment
- Universal and equal access to HBV/HCV therapy
- Acceptance of and adherence to European treatment protocols

Expansion of research resources under the 7th and 8th Research Framework Programmes of the EU

Summit Conference
Hepatitis B and **Hepatitis C**
Brussels, October 2010



www.hepsummit2010.org

Thank you!